BioSpace News Archive

Lannett Company, Inc. shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g.

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”).

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that members of the Zimmer Bioment management team will be presenting at the Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 10:15 a.m. Eastern Time.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2023 after the close of trading on Tuesday, May 2.

Nexcella Inc. announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation to be held in Paris, France, 23-26 April 2023.

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced it is expanding the age eligibility criterion to include children ages 5 to 17 years, previously restricted to ages 13 to 17 years.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects in China for its self-developed innovative intestinal-restricted JAK inhibitor LNK01003.

DarioHealth Corp., a leader in the global digital therapeutics market, announced that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer.

After twenty years as one of the first personalized oncology companies, Indivumed announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience.